Sabirnetug
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
1
Recruiting
0
Completed
2
Sites
83
Countries
5
Endpoints
54
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 54 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 13 of 54 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
4
3
2
1
1
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| ALTITUDE-ADA Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) | Sabirnetug Alzheimer’s disease | Alzheimer's disease | Ph 2 | Active, not recruiting | 68 | Oct 2026 | 1 | |
| INTERCEPT-ADA Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD | Sabirnetug Alzheimer’s disease, MCI / preclinical Alzheimer’s | MCI due to AD | Ph 1 | Completed | 17 | Jun 2023 | - | |
| NCT06511570A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants | Sabirnetug Alzheimer’s disease | Age ≥50 | Ph 1 | Completed | 1 | Sep 2024 | - |
Showing 1-3 of 3 trials